Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Daniel J. Rader, MD

Daniel J. Rader, MD Physician

Associate Director, Institute for Translational Medicine and Therapeutics Chief, Division of Translational Medicine and Human Genetics Director, Preventive Cardiovascular Program Seymour Gray Professor of Molecular Medicine Professor of Medicine in Genetics Professor of Pediatrics Professor of Pharmacology

Languages spoken:

  • Spanish

Dr. Rader is employed by Penn Medicine.

About Dr. Daniel J. Rader

Recognized annually in Philadelphia magazine's Top Docs issue from 2004 through 2017

Recognized by America's Top Doctors, 2007, 2008, 2010, 2012-14

Recognized by Best Doctors in America 2003-2004, 2005-2006, 2009-2010, 2011-2012, 2013-2014

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Patient Comments

Clinical Specialties

Specialty:

  • Cardiology
  • Medical Genetics

Programs & Centers:

Board Certification:

  • Internal Medicine, 1987

Clinical Expertise:

  • Cardiac Risk Reduction
  • Cardiology Risk Intervention
  • Cholesterol and Lipid Disorders
  • Genetic and Rare Diseases Treatments and Procedures
  • High Cholesterol (Hypercholesterolemia)
  • Hyperlipidemia (Hyperlipoproteinemia)
  • Hypertension
  • Lipid Disorders
  • Metabolic Diseases
  • Preventive Heart Care

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Medical College of Pennsylvania
Residency: Yale-New Haven Hospital

Memberships

American Association for the Advancement of Science, National American College of Physicians, National American Federation for Medical Research, National American Heart Association , National American Society for Clinical Investigation, National Delaware Affiliate, American Heart Association Pennsylvania, Local Department of Biochemistry, University of Alberta, Canada, International National Committee for Quality Assurance , National National Institutes of Health, National

Hospital Affiliation

Dr. Rader is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Research Interests
The Rader laboratory is focused on two major themes: 1) novel pathways regulating lipid and lipoprotein metabolism and atherosclerosis inspired by unbiased studies of human genetics; 2) factors regulating the structure and function of high density lipoproteins and the process of reverse cholesterol transport and their relationship to atherosclerosis. A variety of basic cell and molecular laboratory techniques, mouse models, and translational research approaches are used in addressing these questions.

Some examples of ongoing projects are:
1) The roles of sortilin (gene SORT1) and tribbles-1 (gene TRIB1) in lipoprotein metabolism and atherosclerosis. Variants at the SORT1 locus are among the most strongly associated with LDL cholesterol and (coronary artery disease) in the human genome, and variants at the TRIB1 locus are significantly associated with all major plasma lipid traits and CAD. A variety of tissue-specific deleted mouse models, gene targeting in iPS cells with differentiation to hepatocytes, and cell biologic and biochemical approaches are being employed.

2) Functional genomics and mechanistic studies of a number of additional genes at loci significantly associated with lipid and metabolic traits, CAD, or other cardiovascular traits. Most of these genes harbor rare coding variants associated with these traits. In addition to elucidating fundamental mechanisms by which the protein influences relevant biology, the influence of specific mutations on protein structure and function are being explored.

3) Molecular regulation of HDLmetabolism and reverse cholesterol transport using cells, mice, and humans

4) Deep phenotyping of humans with low-frequency and rare variants in genes influencing lipid and cardiovascular traits, including the generation of iPS cells and differentiation to a variety of relevant cell types

Research Lab:
11th floor, Smilow Center for Translational Research

Clinical Research:
9th floor Maloney Building, Hospital of The University of Pennsylvania

Selected Publications:

Dron JS, Wang J, Low-Kam C, Khetarpal SA, Robinson JF, McIntyre AD, Ban MR, Cao H, Rhainds D, Dubé MP, Rader DJ, Lettre G, Tardif JC, Hegele RA: Polygenic determinants in extremes of high-density lipoprotein cholesterol. J Lipid Res : 2017.

Zhao W, Rasheed A, Tikkanen E, Lee JJ, Butterworth AS, Howson JMM, Assimes TL, Chowdhury R, Orho-Melander M, Damrauer S, Small A, Asma S, Imamura M, Yamauch T, Chambers JC, Chen P, Sapkota BR, Shah N, Jabeen S, Surendran P, Lu Y, Zhang W, Imran A, Abbas S, Majeed F, Trindade K, Qamar N, Mallick NH, Yaqoob Z, Saghir T, Rizvi SNH, Memon A, Rasheed SZ, Memon FU, Mehmood K, Ahmed N, Qureshi IH, Tanveer-Us-Salam, Iqbal W, Malik U, Mehra N, Kuo JZ, Sheu WH, Guo X, Hsiung CA, Juang JJ, Taylor KD, Hung YJ, Lee WJ,: Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nat Genet : 2017.

Tuteja S, Wang L, Dunbar RL, Chen J, DerOhannessian S, Marcovina SM, Elam M, Lader E, Rader DJ: Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy. Pharmacogenet Genomics. 27 (8): 285-293,2017.

Bajaj A, Damrauer SM, Anderson AH, Xie D, Budoff MJ, Go AS, He J, Lash JP, Ojo A, Post WS, Rahman M, Reilly MP, Saleheen D, Townsend RR, Chen J, Rader DJ: Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort). Arterioscler Thromb Vasc Biol : 2017.

Koekemoer AL, Codd V, Masca NGD, Nelson CP, Musameh MD, Kaess BM, Hengstenberg C, Rader DJ, Samani NJ : Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity. Arterioscler Thromb Vasc Biol : 2017.

Khetarpal SA, Zeng X, Millar JS, Vitali C, Somasundara AVH, Zanoni P, Landro JA, Barucci N, Zavadoski WJ, Sun Z, de Haard H, Toth IV, Peloso GM, Natarajan P, Cuchel M, Lund-Katz S, Phillips MC, Tall AR, Kathiresan S, DaSilva-Jardine P, Yates NA, Rader DJ: A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nat Med : 2017.

Small AM, Kiss DH, Zlatsin Y, Birtwell DL, Williams H, Guerraty MA, Han Y, Anwaruddin S, Holmes JH, Chirinos JA, Wilensky RL, Giri J, Rader DJ: Text mining applied to electronic cardiovascular procedure reports to identify patients with trileaflet aortic stenosis and coronary artery disease. J Biomed Inform 72 : 77-84,2017.

Dunbar RL, Movva R, Bloedon LT, Duffy D, Norris RB, Navab M, Fogelman AM, Rader DJ.: Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. Clin Transl Sci : 2017.

Döring Y, Noels H, van der Vorst EPC, Neideck C, Egea V, Drechsler M, Mandl M, Pawig LB, Jansen Y, Schröder K, Bidzhekov K, Megens RTA, Theelen W, Klinkhammer BM, Boor P, Schurgers LJ, van Gorp RH, Ries C, Kusters PJH, van der Wal AC, Hackeng TM, Gäbel G, Brandes RP, Soehnlein O, Lutgens E, Vestweber D, Teupser D, Holdt LM, Rader DJ, Saleheen D, Weber C: Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity: Evidence from Mouse and Human Studies. Circulation. 136 (4): 388-403,2017.

Saleheen D, Haycock PC, Zhao W, Rasheed A, Taleb A, Imran A, Abbas S, Majeed F, Akhtar S, Qamar N, Zaman KS, Yaqoob Z, Saghir T, Rizvi SN, Memon A, Mallick NH, Ishaq M, Rasheed SZ, Memon FU, Mahmood K, Ahmed N, Frossard P, Tsimikas S, Witztum JL, Marcovina S, Sandhu M, Rader DJ, Danesh J.: Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol 5 (7): 524-533,2017.

View all publications

Academic Contact Info

Perelman School of Medicine
University of Pennsylvania
11-125 Smilow Center for Translational Research
3400 Civic Center Blvd


Philadelphia, PA 19104-5158
Phone: (215) 573-4176
Fax: (215) 573-8606
Patient appointments: 800-789-7366 (PENN)

Related Links